In the 2 August press release announcing the approval, Adrian Rawcliffe, Adaptimmune CEO also outlined the company's plans for other therapies. He said Adaptimmune plans, "to progress lete-cel, the next late-stage investigational treatment in our sarcoma franchise, with a rolling BLA submission to the FDA next year."